CallDeflectAI Helps Address Staff Shortages in Contact Centers

BullFrog AI Strengthens Capabilities of its AI Platform Through Expansion of Licensing Agreement With Johns Hopkins Applied Physics Laboratory

Samsung Biologics and Pfizer announce strategic collaboration for long-term manufacturing of biosimilars portfolio

Yeast Protein Expression Process

Purolite Grows Bioprocessing Production Capacity with New U.S. Manufacturing Facility

Landenberg site strengthens supply to support lifesaving therapeutics for global customers

AARDEX Partners with Mevia to Test Evolution of Real-Time Adherence Technology

AARDEX Partners with Mevia to Test Evolution of Real-Time Adherence Technology Integration of AARDEX MEMS AS and MEMS Mobile technology with Mevia's Medose dispenser offers opportunity to pilot next stage in reusable and real-time adherence solutions.

Qlucore presents promising results in the field of lung cancer diagnosis

Qlucore, listed on Nasdaq First North, can now present the first results from an EU-funded project for improved diagnosis of lung cancer. The new classification model not only separates different subgroups of primary lung cancer but also indicates whether the tumor sample is a metastasis of breast, colorectal, or kidney cell cancer.

Mural Health and ClinOne Partner to Maximize Patient Experience While Minimizing Site Burden

Mural Health and ClinOne Partner to Maximize Patient Experience While Minimizing Site Burden Strategic partnership integrates next-generation patient support and payment solutions for participants and sites alike

Inizio launches strategic engagement offering to transform customer experiences

BioIVT to Host an Advanced In Vitro ADME Strategies Symposium in Copenhagen

Presenters will discuss the ICH M12 Drug Interaction Studies Guideline, and novel ADME models and methodologies.

Abzena appoints Thomas Castellano as Chief Financial Officer

Abzena, the leading end-to-end integrated CDMO for complex biologic molecules and Antibody Drug Conjugates (ADCs) has announced the appointment of Thomas Castellano, as Chief Financial Officer.

Micropep Boosts Leadership Team with Industry Veteran in Regulatory Science

Dr. Kevin Leiner to spearhead market authorizations for Micropep's groundbreaking natural micropeptide-based crop protection products.

Almaden Genomics Names Ellen Gordon Vice President, Head of Business Development

Almaden Genomics has named Ellen Gordon as Vice President, Head of Business Development. Gordon has worked for more than two decades on behalf of pharmaceutical and biotech companies to deliver insights and much-needed solutions, perfectly suiting her to help Almaden partner with clients and labs to accelerate genomic research and discovery through streamlined bioinformatics.

Globally Cancer Biological Therapy Demand – sales out Till 2032

The global cancer biological therapy industry size was exhibited at USD 98.85 billion in 2022 and is projected to hit around USD 214 billion by 2032, growing at a CAGR of 8.03% during the forecast period 2023 to 2032.

Phastar Statistics Manager Wins Prestigious DIA Award

Phastar Statistics Manager Wins Prestigious DIA Award Stephen Corson chosen to receive the DIA 2023 Global Inspire Award for Community Engagement. London, UK and Durham, NC – 6 June 2023: Stephen Corson, Statistics Manager at specialist biometrics contract research organization (CRO) Phastar, has been chosen to receive the DIA 2023 Global Inspire Award for Community Engagement.

Samsung Biologics accelerates timeline of new fifth plant to be operational by April 2025

Microbialtec Develops Custom Microbial Expression and Production Services with Cutting-edge Solutions

CD Biosciences Launches C.elegans Proteins to Support Research in The Developmental Biology

Creative Biogene Released Cutomized CRISPR/Cas13 RNA Editing Services to Support Genomic Engineering

Owkin powers a new era in oncology research with MOSAIC – an unprecedented $50 million spatial atlas of cancer cells

The first initiative of its kind using spatial omics technology, MOSAIC holds the potential to open a new field in oncology treatment research. Collaborating with Gustave Roussy, the University of Pittsburgh through the UPMC Hillman Cancer Center, Lausanne University Hospital, Uniklinikum Erlangen/Friedrich-Alexander- Universität Erlangen-Nürnberg, Charité - Universitätsmedizin Berlin, NanoString Technologies and other providers of analytical instrumentation and assays for spatial biology, Owkin will invest $50 million to build MOSAIC. It will use 7,000 tumor samples from patients, making it over 100 times larger than any existing spatial omics datasets. Owkin and the MOSAIC partners will mine this resource for immune-oncology disease subtypes in pursuit of biomarkers and novel therapies.